CHICAGO - A $34 device that plugs into the audio jack of a smartphone was nearly as effective as far more costly diagnostic blood testing equipment in identifying antibodies for HIV and syphilis in a pilot study in Africa, U.S. researchers said on Wednesday.

The mobile lab device, known as a dongle, cost $34 to make, compared with more than $18,000 for the gold standard diagnostic equipment. In a pilot study, the device performed all of the mechanical, optical and electronic functions of a lab-based blood test in 15 minutes, using only power drawn from the smartphone.

Study: $34 Smartphone Device Could Improve HIV Diagnosis

It was developed by a team lead by Samuel Sia, an associate professor at the Department of Biomedical Engineering at Columbia University in New York.

Study: $34 Smartphone Device Could Improve HIV Diagnosis

To test its effectiveness, health care workers in Rwanda used the tool to do finger-prick blood tests on 96 patients, including women who were at risk of passing sexually-transmitted diseases to their unborn children.

Study: $34 Smartphone Device Could Improve HIV Diagnosis

The team compared the results with standard enzyme-linked immunosorbent assay or ELISA testing, and found the results were nearly as accurate. The test has a sensitivity of 92 to 100 percent, a measurement of how often the tests accurately identified the target antibodies, and it had a specificity of 79 to 100 percent, an indicator of how well the test did at ruling out people who were not infected.

"Our work shows that a full laboratory-quality immunoassay can be run on a smartphone accessory," Sia said in a statement.

The researchers estimate that with syphilis, a test with only 70 to 80 percent sensitivity and specificity that was performed at the point of care could reduce deaths tenfold compared with a perfectly accurate lab-based test, because the non-lab test would be more likely to increase syphilis diagnosis.

The study was backed by a grant from the Gates Foundation and several other funders and published on Wednesday in the journal .

The researchers are planning a larger-scale clinical trial with the goal of winning approval by the World Health Organization for use in developing countries.